In head and neck squamous cancer cells, silencing MCPs did not render the cells susceptible to complement attack, suggesting that tumor cells can compensate for the lack of a single MCP by upregulating the expression of other complement restriction proteins [52]. This evidence concerns the gene CD46 and neoplasm.